Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-04-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines across rare blood disorders, autoimmune disease, oncology, cardiovascular and metabolic disease, and partnered RNA therapeutics.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Validation, But 2031 Needs a Second Engine
The setup is no longer a pure science experiment because an approved CRISPR therapy exists and liquidity is strong. But the decisive rerating still requires wholly owned programs to prove CRISPR can capture more value than a partner-led rare-disease launch allows today.

Analysis

Thesis
An approved CRISPR therapy and a very strong balance sheet reduce existential risk, but the real 2031 upside comes from proving at least one wholly owned program can become a meaningful second franchise; if that happens, CRSP can rerate from a cash-backed platform option into a multi-asset gene-editing company.
Last Economy Alignment
AI should speed target selection, construct design and portfolio learning, while CRISPR still captures value through regulated evidence, IP and manufacturing trust. The main drag is that its first commercial asset is still largely controlled by Vertex.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.3x (from 5 most recent analyses)
Reasoning
Today the market mostly pays for cash, one validated product, and platform optionality. By 2031, the multiple can expand if investors are underwriting two things at once: durable CASGEVY economics plus at least one wholly owned franchise in autoimmune, cardio-metabolic or thrombosis. That is enough for a meaningful rerating, but not enough to justify a heroic hypergrowth case because clinical proof, treatment-network throughput and partner control still matter.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The biggest risks are not generic biotech cash risk but proof and control. CRSP now has real modality validation, yet the path to a much larger 2031 valuation still runs through slow treatment-center scaling for CASGEVY, regulator-heavy development of wholly owned programs, and a structural value-capture constraint because Vertex controls the lead commercial asset.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.39
AI can help this company design and prioritize new medicines faster, but the real value still sits in hard-to-copy things like clinical proof, regulatory trust and manufacturing know-how. That gives it a real edge, though not a full toll-booth position because Vertex still controls most of the first product's commercial machinery.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$83.35
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case